Ireland
--:--IST
Latest
Clinical Trials in Canada / NCT06461741
Recruiting Not applicable

EMG Biofeedback Training to Improve Balance in Individuals with Multiple Sclerosis

NCT06461741 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2024-12-03

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

Integrated Dual-task EMG Biofeedback Training (EMG-BF)Traditional Balance Exercise Training (BAL-EX)

Integrated Dual-task EMG Biofeedback Training (EMG-BF): The intervention is an exercise training that is facilitated by feedback derived from electrical muscle activity measured through electromyography (EMG). An EMG Biofeedback software uses a machine learning algorithm to identify the desired movements and reinforce them by displaying feedback on a computer monitor in the form of videogame control. The EMG acquisition hardware must have at least 4 sensor channels and a sampling rate of \>1KHz. Other than these specifications, any generic EMG amplifier can be used. The effect of the "device" is therefore primarily defined by the software. An in-depth description of the software and hardware systems is published in the cites study, "An EMG-Based Biofeedback System for Tailored Interventions Involving Distributed Muscles". In this trail is the Explore+ ExG amplifier which is sold by Mentalab.

Traditional Balance Exercise Training (BAL-EX): This intervention is a time-matched active comparator for the EMG-BF intervention. A sequence of seven traditional, balance exercises, taking 1-3 minutes each, is repeated for a total of 30 minutes on each of 18 sessions in the 6-week intervention period. The exercises are ones that challenge the coordination and strength of postural muscles in the presence of various vestibular stimuli. The specific exercises are described in the Arm description.

Study summary

The goal of this clinical trial is to test the impact of a novel dual-task EMG Biofeedback training method for improving balance in individuals living with multiple sclerosis. The main question\[s\] it aims to answer are:

* Does dual-task EMG biofeedback training deliver lasting balance benefits up to 3 months following the intervention?
* Are the benefits greater than those for participation in traditional balance training exercises?
* Do the benefits vary with the severity of disability?

Participants will receive either EMG Biofeedback (EMG-BF) training or traditional balance exercise (BAL-EX) training. Both treatments involve three 30-minute sessions of the training every week for 6 weeks (18 sessions). During the sessions, participants in the EMG-BF treatment group will perform targeted exercises using feedback from adhesive (sticker) sensors on their arms and legs. Participants in the BAL-EX treatment group will following an instructor through balance training movements that are traditionally prescribed by physiotherapists to improve balance. Measurements will be taken at the beginning of the study, after six weeks of training, and three months after the end of training.

Researchers will compare the groups to see if balance and related outcomes are improved more by 6-weeks of EMG-BF training than BAL-EX.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18-80 years with a formal diagnosis of MS. * Participants must be ambulatory and report problems with walking and/or balance. * Have stable disease with no relapses in the last 3 months. * Agreement to not introduce or change the dosage of pharmaceutical treatments during the study period. This includes intramuscular injections (e.g., Botox), intravenous, and orally administered drugs. * Agreement to maintain the frequency, duration and intensity of physical therapy or any alternate therapies (e.g., massage, osteopathic, chiropractic, etc.) for the duration of the trial. Exclusion Criteria: * Unable to follow instructions due to cognitive deficit or language barrier * Presence of visual disorders that prevent meaningful interaction with the intervention interface. * Unable to maintain stable pharmaceutical treatment for the duration of the study. * Unable to maintain the frequency, duration and intensity of physical therapy or alternate therapies outside of the trial for the duration of the trial. * Received Botox treatment within 3 months of the onset of the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
McMaster University Hamilton Ontario Recruiting

More McMaster University trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06461741 on ClinicalTrials.gov ↗ ← All trials in Canada